Beijing Chunlizhengda Medical Instruments Co., Ltd. (“Chunli Medical”) has published its 2025 Environmental, Social and Governance Report covering the period 1 January-31 December 2025. Key disclosures follow:

Environmental Metrics • Total electricity use reached 7.15 million kWh, equal to 68.41 kWh per RMB 10,000 of revenue; solar installations at the Daxing base produced 18,400 kWh. • Fuel consumption for the vehicle fleet was 38,860 litres of gasoline. • Scope 1 emissions were 17.98 tonnes; Scope 2 emissions 3,992.40 tonnes, bringing combined Scope 1-2 output to 4,010.38 tonnes (up 32.70 % year-on-year). • Water withdrawal totalled 15,700 tonnes, or 0.15 tonne per RMB 10,000 of revenue; 9,691 tonnes of wastewater were treated on-site before discharge to municipal facilities. • Hazardous waste generation stood at 17.29 tonnes, while non-hazardous waste reached 626 tonnes; compliant treatment rate was 100 %.

Climate Targets and Governance • A three-tier ESG structure—Board of Directors, Strategy Committee and ESG Working Group—oversees policy and execution. • Chunli Medical targets a 3 % reduction in emissions intensity by 2035 (base year 2025) through energy-efficiency upgrades, renewable energy and low-carbon R&D.

Social Indicators • Headcount totalled 1,078, with R&D personnel making up 25.70 % (277 employees). • Employee turnover was 15 %; no work-related fatalities or lost-time injuries were reported for 2023-2025. • Training reached 192 sessions; average training hours were 4.5 for men and 4.0 for women. • Workplace-safety investment amounted to RMB 303,000, and work-injury insurance payments were RMB 876,300.

Supply Chain and Governance • Qualified supplier list includes 214 vendors, split 48 % North China and 52 % South China; all were assessed under compliance and ESG criteria. • The company recorded zero incidents of corruption, anti-trust or data-security breaches during the year.

R&D and Innovation • R&D expenditure was RMB 118.50 million, representing 11.35 % of main-business revenue; 56 invention patent applications were filed and 42 granted, bringing the valid invention patent portfolio to 191.

Community Investment • Cash donations of RMB 0.56 million and in-kind supplies worth RMB 0.04 million were provided, including flood-relief materials for Beijing and Hebei and continued funding for the “Chunli Sunshine Program” artificial-joint charity initiative.

Chunli Medical’s Board approved the ESG report on 30 March 2025 and affirmed its responsibility for the authenticity, accuracy and completeness of the disclosed information.